Pyxis Oncology, Inc.
PYXS
$1.70
$0.010.59%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -14.17% | -82.53% | -82.53% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -14.17% | -82.53% | -82.53% | -100.00% |
| Cost of Revenue | -- | 402.74% | -100.00% | -100.00% | -100.00% |
| Gross Profit | -- | -26.81% | -82.00% | -82.00% | -100.00% |
| SG&A Expenses | -11.72% | -12.78% | -18.00% | -30.52% | -30.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.68% | 17.12% | 6.13% | 4.26% | 3.36% |
| Operating Income | -0.01% | -24.82% | -28.37% | -25.47% | -29.32% |
| Income Before Tax | 17.50% | 1.59% | -72.55% | -65.81% | -68.50% |
| Income Tax Expenses | 164.05% | 164.05% | -- | -- | -- |
| Earnings from Continuing Operations | 14.17% | -2.96% | -69.27% | -62.64% | -64.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 14.17% | -2.96% | -69.27% | -62.64% | -64.75% |
| EBIT | -0.01% | -24.82% | -28.37% | -25.47% | -29.32% |
| EBITDA | 3.29% | -23.56% | -31.38% | -27.51% | -31.38% |
| EPS Basic | 16.67% | -0.20% | -50.13% | -25.05% | -12.73% |
| Normalized Basic EPS | -1.95% | -29.55% | -20.43% | -0.29% | 9.42% |
| EPS Diluted | 16.64% | -0.46% | -50.46% | -25.32% | -12.98% |
| Normalized Diluted EPS | -1.95% | -29.55% | -20.43% | -0.29% | 9.42% |
| Average Basic Shares Outstanding | 3.07% | 6.34% | 13.73% | 23.95% | 38.76% |
| Average Diluted Shares Outstanding | 3.07% | 6.34% | 13.73% | 23.95% | 38.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |